The CD200R1 microglial inhibitory receptor as a therapeutic target in the MPTP model of Parkinson's disease.

ABSTRACT:

Background

It is suggested that neuroinflammation, in which activated microglial cells play a relevant role, contributes to the development of Parkinson's disease (PD). Consequently, the modulation of microglial activation is a potential therapeutic target to be taken into account to act against the dopaminergic neurodegeneration occurring in this neurological disorder. Several soluble and membrane-associated inhibitory mechanisms contribute to maintaining microglial cells in a quiescent/surveillant phenotype in physiological conditions. However, the presence of activated microglial cells in the brain in PD patients suggests that these mechanisms have been somehow overloaded. We focused our interest on one of the membrane-associated mechanisms, the CD200-CD200R1 ligand-receptor pai

SUBMITTER: Rabaneda-Lombarte N 

PROVIDER: S-EPMC8025338 | biostudies-literature | 2021 Apr

REPOSITORIES: biostudies-literature